Arecor Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was £15.38 Mil.
Warning Sign:
If a company builds assets at 50.7% a year, faster than its revenue growth rate of 28.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Arecor Therapeutics's average Total Assets Growth Rate was -3.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 83.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 50.70% per year.
During the past 7 years, Arecor Therapeutics's highest 3-Year average Total Assets Growth Rate was 83.90%. The lowest was -3.40%. And the median was 44.40%.
The historical data trend for Arecor Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Arecor Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (LSE:AREC) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Arecor Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Arecor Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Arecor Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Arecor Therapeutics (LSE:AREC) Business Description
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:AREC has been successfully added to your 